Irish drug developer Amarin Corp. PLC, with research headquarters in the Mystic section of Stonington, has signed a pair of global suppliers as it braces for marketing its treatment for curbing heart-harming compounds in the blood.
Dublin-based Amarin said Equateq Ltd. of Scotland and South Korea’s Chemport Inc. have agreed to provide Amarin with the active pharmaceutical ingredient for its AMR101 compound currently in advanced clinical trials. AMR101 is aimed at reducing artery-clogging triglyceride levels in humans.
It also signed Catalent Pharma Solutions LLC., of Somerset, N.J., and Banner Pharmacaps Europe B.V., of High Point, N.C., to provide the soft-gel encapsulation for AMR101.
Financial terms were unavailable.
Amarin CEO Joseph Zakrzewski said these agreements expand Amarin’s entire supply chain and provide the company with significantly greater global capacity and diversification in preparation for the commercial launch of AMR101.
